Last reviewed · How we verify
SQIN-Furosemide
At a glance
| Generic name | SQIN-Furosemide |
|---|---|
| Also known as | Lasix ONYU |
| Sponsor | SQ Innovation, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers (PHASE1)
- Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure (PHASE3)
- Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure (PHASE2)
- A Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SQIN-Furosemide CI brief — competitive landscape report
- SQIN-Furosemide updates RSS · CI watch RSS
- SQ Innovation, Inc. portfolio CI